Sterling Capital Management’s UroGen Pharma URGN Stock Holding History

Sterling Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.09K	Sell	247 -208	-46%	-$5.64K	﹤0.01%	2273
2026 Q1	$8.18K	Sell	455 -129	-22%	-$2.59K	﹤0.01%	2487
2025 Q4	$13.7K	Buy	584 +60	+11%	+$1.3K	﹤0.01%	2448
2025 Q3	$10.5K	Buy	524 +220	+72%	+$3.95K	﹤0.01%	2464
2025 Q2	$4.17K	Buy	304 +109	+56%	+$1.05K	﹤0.01%	2610
2025 Q1	$2.16K	Sell	195 -122	-38%	-$1.3K	﹤0.01%	2564
2024 Q4	$3.38K	Buy	317 +265	+510%	+$3.17K	﹤0.01%	2611
2024 Q3	$660	Buy	+52	New	+$772	﹤0.01%	2746

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Sterling Capital Management's URGN Position: Q2 2026 in Review

Sterling Capital Management reduced its UroGen Pharma (URGN) stake by 46% in Q2 2026, selling an estimated $5.64K and leaving 247 shares worth $9.09K. The position accounts for ﹤0.01% of the portfolio, ranked #2273.

Sterling Capital Management first reported a position in URGN in Q3 2024 and has held it in 8 quarters since. The position peaked at $13.7K in Q4 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Sterling Capital Management held 247 shares of UroGen Pharma worth $9.09K as of Q2 2026.
Sterling Capital Management sold 208 UroGen Pharma shares in Q2 2026, an estimated $5.64K.
UroGen Pharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2273 holding.
Sterling Capital Management first reported a position in UroGen Pharma in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's UroGen Pharma position peaked at $13.7K in Q4 2025.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.